Oxycodone 10mg Pink K56

Product Beschrijving

Oxycodone Hydrochloride 10 mg Tablets USP (debossed with “K” on one side and “56” on the reverse) provide an immediate-release oral opioid formulation designed for rapid-onset analgesic relief. Acting as a pure full opioid agonist, oxycodone binds to stereospecific $\mu$-opioid receptors distributed throughout the brain and spinal cord. This binding inhibits the release of neurotransmitters in ascending pain pathways, elevating the pain threshold and dampening the physiological and emotional impact of acute nociceptive pain.

Physical Specifications & Manufacturing Details

• Imprint: “K” debossed on one side; “56” debossed on the reverse

• Visual Characteristics: Pink, round, biconvex tablet with a functional score line

• Strength / Active Moiety: 10 mg Oxycodone Hydrochloride USP

• Manufacturer / Labeler: KVK-Tech, Inc.

• National Drug Code (NDC): 10702-0056

• Dosage Form: Immediate-release oral tablet

Klinische farmacokinetiek

• Absorption & Onset: Rapid gastrointestinal absorption with noticeable analgesic effects within 15 to 30 minutes; peak plasma concentrations ($C_{\max}$) are achieved within 1 to 2 hours post-dose.

• Metabolism: Extensively metabolized by the liver primarily via CYP3A4 (forming noroxycodone) and secondarily via CYP2D6 (forming oxymorphone).

• Elimination & Half-Life: Eliminated primarily via renal excretion with an average elimination half-life of approximately 3.2 to 4 hours in healthy adults.

Mandatory Boxed Warnings & Safety Compliance

• Addiction, Abuse, and Misuse: Oxycodone exposes patients to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing and monitor regularly.

• Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor patients closely, especially during treatment initiation or dose titration.

• Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can result in fatal respiratory arrest. Keep stored in a secure, locked location.

• Risks from Concomitant Use with CNS Depressants: Co-administration with benzodiazepines, alcohol, or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.

• Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged maternal use during pregnancy can lead to life-threatening neonatal withdrawal requiring management according to neonatology protocols.